Novel drops for a variety of indications are under investigation.

Two novel, dropless technologies for keratoconus and dry eye disease make major advances with more to come later in 2023.

The VEGA-2 pivotal trial is investigating Nyxol alone and Nyxol with adjunctive low-dose pilocarpine therapy for the treatment of presbyopia.

Justin Schweitzer, OD, gives a brief overview of his EyeCon 2022 presentations, reflecting on pipeline advancements made in optometry in 2022.

As the first and only preservative-free formulation of latanoprost, IYUZEH 0.005% is approved to reduce IOP in patients with open-angle glaucoma or ocular hypertension.

The preservative-free, multi-dose contact lens rehydrating drops are expected to hit the market in early 2023.

Considering safety and efficacy of new drops and the potential impact on your patients.

Intravitreally injected anti-VEGF drugs are undergoing investigation as researchers look for new treatment options.

The FDA granted orphan drug designation to BRM424 (BRIM Biotechnology) to treat neurotrophic keratitis (NK).

The positive 3-month efficacy and safety results from Azura Ophthalmic's Phase 2b study of AZR-MD-001 0.5% in Meibomian Gland Dysfunction (MGD) met its co-primary endpoints.

The submission is supported by positive phase 3 data, which shows quick reversal of dilation and favorable safety and tolerability.

Rob Sambursky, MD, president of Verséa Ophthalmics, sat down with David Hutton of Ophthalmology Times to discuss 3 major developments in the company pipeline.

This acquisition for Alcon means a growing ophthalmic portfolio of commercial products and development pipeline.

Jack Phu, OD, MPH, PhD, with UNSW Sydney, discusses key takeaways from his AAOpt 2022 presentation that looked at visual fields in 2022.

Ocuphire seeks to develop and commercialize Nyxol for the reversal of mydriasis, presbyopia and night vision disturbances.

Aziz Mottiwala, the Chief Commercial Officer at Tarsus Pharmaceuticals, shares a pipeline update.

The submission of 24-month efficacy data from DERBY and OAKS is classified as a Major Amendment to the New Drug Application, which delays the PDUFA target action date until February 2023.

The CHAMP phase 3 study shows strong safety and efficacy of NVK002 for the treatment of myopia.

The web-based, self-guided software application is accessed through touchscreen mobile devices.

Water gradient tech, high-tech materials, and new therapies offer more options.

Johnson & Johnson Vision receives FDA-approval of lens parameter expansion for their ACUVUE Abiliti Overnight Therapeutic Lenses for Myopia Management.

Melissa Barnett, OD, from the University of California, Davis Eye Center, Sacramento and Davis, CA, described new strategies, technologies, and drug classes to treat chronic conditions that include myopia, Demodex infestation, meibomian gland dysfunction, glaucoma drug delivery, advancements in corneal and cataract surgeries, and presbyopia

Brandon Barber, chief marketing officer at Heru, shares about the company's new dark adaptation modality, which they announced during the 2022 Vision Expo West, as well as other advancements in the pipeline.

Azura has secured funding to support its 2-stage study evaluating the safety, tolerability, and efficacy of AZR-MD-001, its leading candidate, for patients with contact lens discomfort who show signs of meibomian gland dysfunction.

Brad Sutton, OD, FAAO, FORS, shares highlights from his SCOPA 2022 presentation, "Topical Pharmacology Rounds."

Latest data from phase 3 studies finds increased effects over time with intravitreal pegcetacoplan for geographic atrophy secondary to age-related macular degeneration.

Latest transaction, totaling approximately $770 million, adds key commercial products and clinical/preclinical product candidates in the pipeline.

Ranibizumab-eqrn will offer greater treatment access and choice for patients, payors, and providers in the US.

COMET-3 is the second of 3 studies in the AR-15512 Registrational Phase 3 Program, which is slated for completion by 2023.

If approved, pegcetacoplan—an investigational, targeted C3 therapy—will be the first-ever treatment for GA.